|
|
|
ALX Oncology to Collaborate with Merck on Ph 2 trials of ALX148 + KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer
“ALX148 was designed for use in combination to maximize clinical activity with a range of anti-cancer agents. We believe that blocking the CD47 myeloid checkpoint pathway bridges the innate and adaptive immune response against cancer to enhance efficacy. This collaboration builds upon the compelling combination activity observed in patients with ALX148 and KEYTRUDA,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “Our goal is to transform treatment options for patients with cancer by developing ALX148 as a foundational checkpoint immunotherapy.”
|
|
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
"We are excited to expand our agreement with Pfizer to evaluate the clinical combination of IDE196 and crizotinib in MUM and other solid tumors with GNAQ or GNA11 mutations," said Mick O'Quigley, Vice President, Head of Development Operations, IDEAYA Biosciences. "Through our translational research we have identified cMET expression as a potential biomarker, and we are excited to explore this rational combination between IDE196 and crizotinib clinically," said Mark Lackner, Ph.D., Senior Vice President, Head of Biology and Translational Sciences.
|
|
|
Roche acquired Ireland based company Inflazome for $451M
On 21st September 2020, Inflazome announced that it has closed a shared purchase agreement with Roche for $451M. With this deal, Roche gains full rights to Inflazome’s pipeline of oral NLRP3 inhibitors as treatments for Parkinson’s and other diseases. Roche will continue to further develop NLRP3 inhibitors to treat different spectra of diseases.
“We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well-positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases,”- Matt Cooper, Chief Executive Officer, Inflazome.
|
|
Palladio Bioscience, Inc. secures $20 M series B funding to fuel its phase 3 ALERT study for Autosomal Dominant Polycystic Kidney Disease
On 25th September 2020 Palladio Bioscience, a private clinical-stage biopharma, has raised $20 million Series B funding. The financing round was led by a new investor, Samsara BioCapital, with participation from a new investor, the Roche Venture Fund, and existing investors, Medicxi and Osage University Partners.
Palladio’s phase 3 pipeline, lixivaptan, for Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a potent, selective vasopressin V2 receptor antagonist, which slows kidney function decline in adults with ADPKD. Palladio is currently enrolling ADPKD patients into The ALERT Study (PA-ADPKD-303), the company’s first Phase 3 clinical trial for lixivaptan.
Alex Martin, Chief Executive Officer of Palladio, commented, "We are focused on developing our lead candidate, lixivaptan, for the treatment of ADPKD, an orphan disease with a significant unmet medical need that can impact many generations of a family. This Series B financing will fund our ALERT Study, a Phase 3 trial designed to assess the safety of lixivaptan in ADPKD patients who showed liver chemistry abnormalities or other signs of liver toxicity while taking tolvaptan, the only drug currently approved in the United States for the treatment of ADPKD. We are grateful for the support of the investment community in helping us advance this potential new drug and we welcome Samsara and the Roche Venture Fund to Palladio.”
|
|
Click here for mergers , aquisitions and more business news
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|